Our Company

TALLC is a pre-clinical stage biopharmaceutical company developing our new mechanism medicines to treat acute and chronic conditions in the eye.

Our Mission

To Improve the Lives of Patients by Inventing and Developing Valuable New Ophthalmic Medicines

Our Vision

To be a leading provider of pipeline opportunities in ophthalmics enabling better clinical and commercial outcomes.

Our Advantage

Our pipeline of new mechanism synergistic API, enabled for pan-ocular delivery by our SmartCelleTM and AmyloFlexTMdelivery platforms, developed by our expert team of scientist and industry professionals.

Our Programs

Largely virtual, the high experienced TALLC team will first focus on SmartCelle TA-A001, a micellar formulation of our novel CB2 receptor specific drug candidate:

  • As a topically instilled eye drop for the severe pain and inflammation that occurs after cross-linking surgery for keratoconus

  • As a topical treatment to avoid the pain and inflammation resulting from PRK, LASIK, SMILE and Cataract surgeries
  • TALLC is also developing extended release formulations of our pipeline candidates for treatment of Dry-Eye Disease, Uveitis, AMD and Glaucoma

Meet the team

Management
Team

Scientific
Advisers
Board Of
Directors

CONTACT US

Phone: 514 883 3447

Email: info@tallcinc.com

NEWS

TALLC Corporation Announces Grant of New SmartCelle Patent for
Enhanced Ocular Delivery of TA-A001

Tetra Bio-Pharma and Altus Formulation Form New Company “TALLC” to Exploit TA-A001

TALLC Launches New Ophthalmology Drug WebSite:

https://www.tallcinc.com

TALLC Inc. is an emerging ophthalmology company developing novel mechanism medicines to treat acute and chronic conditions of the eye. Visit our website to learn more about TA-A001,…https://lnkd.in/dTjZ8Nx

Load More...
TALLC Innovation in Vision

© TALLC Inc. 2020